CCR5拮抗剂治疗hiv感染者的癌症风险是增加、降低还是不变?

{"title":"CCR5拮抗剂治疗hiv感染者的癌症风险是增加、降低还是不变?","authors":"Todd McNiff, Bruce J Dezube","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":50834,"journal":{"name":"Aids Reader","volume":"19 6","pages":"218-22, 224"},"PeriodicalIF":0.0000,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged.\",\"authors\":\"Todd McNiff, Bruce J Dezube\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":50834,\"journal\":{\"name\":\"Aids Reader\",\"volume\":\"19 6\",\"pages\":\"218-22, 224\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aids Reader\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aids Reader","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}